Changes in genetic transcription patterns in Jurkat cells treated with Tamoxifen
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA506701 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:In this research, we use DNA microarray analysis to clarify the gene expression responses in Jurkat cells after Tamoxifen treatment. Jurkat cells are a dexamethasone-resistant cell line derived from a T-cell Acute Lymphoblastic Leukaemia sample in relapse
2019-09-02 | GSE122852 | GEO
Project description:Protein glycosylation plays essential roles in regulating innate and adaptive immune response. Previous studies have typically focused on individual protein-glycan interaction or specific glycoform changes associated with T cell activation, yet a systematic characterization of protein glycosylation alterations remains insufficiently elucidated. To address these limitations, we conducted temporally-resolved quantitative multi-proteomic analysis on activated Jurkat T cells. Through an integrative analysis of glycoforms, site-specific glycans, glycoproteins, and glycosylation enzymes, we portrayed the dynamic landscape of protein glycosylation during Jurkat T cell activation. We found the heterogeneity and number of significantly up-regulated intact glycopeptides increased along with stimulation time. For most glycopeptides, their alteration patterns did not correlate well with the abundance of their glycoprotein substrates. Comparative analysis of global peptides, glycopeptides, and phosphopeptides revealed their distinctive changing patterns along Jurkat T cell activation, and only glycosylation demonstrated a steady increase trend with a large proportion of up-regulated glycopeptides. Collectively, this integrated multi-proteomics characterization of activated Jurkat T cells provided insights for the crucial role of glycosylation in modulating immune response, and would aid the development of novel therapeutic strategy targeting glycosylation.
2025-11-30 | PXD058431 | JPOST Repository
Project description:Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with ER-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic manner. In this study we assessed gene expression changes at multiple time points (days 1, 2, 4, 7, 14) after tamoxifen treatment in the ER-positive ZR-75-1 xenograft model that displays significant changes in apoptosis, proliferation and angiogenesis within 2 days of therapy. Hierarchical clustering identified six time-related gene expression patterns, which separated into three groups: two with early/transient responses, two with continuous/late responses and two with variable response patterns. The early/transient response represented reductions in many genes that are involved in cell cycle and proliferation (e.g. BUB1B, CCNA2, CDKN3, MKI67, UBE2C), whereas the continuous/late changed genes represented the more classical estrogen response genes (e.g.TFF1, TFF3, IGFBP5). Genes and the proteins they encode were confirmed to have similar temporal patterns of expression in vitro and in vivo and correlated with reduction in tumour volume in primary breast cancer. The profiles of genes that were most differentially expressed on days 2, 4 and 7 following treatment were able to predict prognosis, whereas those most changed on days 1 and 14 were not, in four tamoxifen treated datasets representing a total of 404 patients. Both early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has significant implications for the timing of biopsies in neoadjuvant biomarker studies.
2010-06-17 | GSE22386 | GEO
Project description:Tamoxifen is the most widely prescribed anti-estrogen treatment for patients with ER-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic manner. In this study we assessed gene expression changes at multiple time points (days 1, 2, 4, 7, 14) after tamoxifen treatment in the ER-positive ZR-75-1 xenograft model that displays significant changes in apoptosis, proliferation and angiogenesis within 2 days of therapy. Hierarchical clustering identified six time-related gene expression patterns, which separated into three groups: two with early/transient responses, two with continuous/late responses and two with variable response patterns. The early/transient response represented reductions in many genes that are involved in cell cycle and proliferation (e.g. BUB1B, CCNA2, CDKN3, MKI67, UBE2C), whereas the continuous/late changed genes represented the more classical estrogen response genes (e.g.TFF1, TFF3, IGFBP5). Genes and the proteins they encode were confirmed to have similar temporal patterns of expression in vitro and in vivo and correlated with reduction in tumour volume in primary breast cancer. The profiles of genes that were most differentially expressed on days 2, 4 and 7 following treatment were able to predict prognosis, whereas those most changed on days 1 and 14 were not, in four tamoxifen treated datasets representing a total of 404 patients. Both early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has significant implications for the timing of biopsies in neoadjuvant biomarker studies. Tamoxifen treated ZR-75 xenograft samples compared to a pooled control. 5 timepoints, replicates and dye swaps, giving a total of 32 arrays
2010-06-17 | E-GEOD-22386 | biostudies-arrayexpress
Project description:Comparison of resting Jurkat/wt vs multiresistant Jurkat/A4 clone
2007-01-09 | E-MEXP-530 | biostudies-arrayexpress
Project description:The cultured cell line Jurkat is frequently employed in studies of T cell function. Here we identified the microRNAs expressed in Jurkat cells in the presence and absence of CD3/CD28mAb treatment.
2010-12-31 | GSE23430 | GEO
Project description:Tamoxifen enhances romidepsin-induced senescence in pancreatic cancer cells. We compared gene-expression profile among untreated control, romidepsin-treated, tamoxifen-treated, and romidepsin plus tamoxifen-treated Panc1 cells.
2021-08-21 | GSE182526 | GEO
Project description:In order to increase the spectral library to study the ocurrence of distinct peptide fragmetation patterns, we analyzed the whole cell proteome of Jurkat cells.
2019-02-25 | PXD005111 | Pride
Project description:The cultured cell line Jurkat is frequently employed in studies of T cell function. Here we identified the microRNAs expressed in Jurkat cells in the presence and absence of CD3/CD28mAb treatment. Analyzed the expression of microRNAs extracted from untreated Jurkat cells as a control and Jurkat cells treated with CD3/CD28mAb.
2010-12-31 | E-GEOD-23430 | biostudies-arrayexpress